TY - JOUR
T1 - Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1
AU - Liu, Huifei
AU - Wang, Sa A.
AU - Schlette, Ellen J.
AU - Xu, Jie
AU - Jorgensen, Jeffrey L.
AU - Cameron Yin, C.
AU - Li, Shaoying
AU - Jeffrey Medeiros, L.
AU - Tang, Guilin
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Chromosome translocation t(16;21)(q24;q22)/RUNX1-RUNX1T3 is an infrequent but recurrent chromosomal abnormality identified in myeloid neoplasms, with only 25 cases have been reported to date. Here, we report eight cases (six women and two men) of myeloid neoplasms associated with t(16;21)(q24;q22): five with therapy-related myeloid neoplasms, two with relapsed acute myeloid leukemia (AML), and one with blast phase of chronic myeloid leukemia. Morphologic and immunophenotypic features include granulocytic dysplasia, blasts with prominent perinuclear hof, large orange-pink granules, long and slim Auer rods, and aberrant expression of CD19. Six patients received AML-based regimens, and five achieved complete remission after initial induction therapy. Our study suggests that myeloid neoplasm with t(16;21)/RUNX1-RUNX1T1 resembles AML with t(8;21)(q22;q22)/RUNX1-RUNX1T1, in regard to morphology, immunophenotype, and response to therapy. Therefore, the clinical management of AML with t(8;21) may provide the best model for patients with myeloid neoplasms with t(16;21).
AB - Chromosome translocation t(16;21)(q24;q22)/RUNX1-RUNX1T3 is an infrequent but recurrent chromosomal abnormality identified in myeloid neoplasms, with only 25 cases have been reported to date. Here, we report eight cases (six women and two men) of myeloid neoplasms associated with t(16;21)(q24;q22): five with therapy-related myeloid neoplasms, two with relapsed acute myeloid leukemia (AML), and one with blast phase of chronic myeloid leukemia. Morphologic and immunophenotypic features include granulocytic dysplasia, blasts with prominent perinuclear hof, large orange-pink granules, long and slim Auer rods, and aberrant expression of CD19. Six patients received AML-based regimens, and five achieved complete remission after initial induction therapy. Our study suggests that myeloid neoplasm with t(16;21)/RUNX1-RUNX1T1 resembles AML with t(8;21)(q22;q22)/RUNX1-RUNX1T1, in regard to morphology, immunophenotype, and response to therapy. Therefore, the clinical management of AML with t(8;21) may provide the best model for patients with myeloid neoplasms with t(16;21).
KW - Myeloid neoplasms
KW - RUNX1/RUNX1T3 rearrangement
KW - Therapy-related
KW - t(16;21)
UR - http://www.scopus.com/inward/record.url?scp=85048038474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048038474&partnerID=8YFLogxK
U2 - 10.1007/s00277-018-3389-3
DO - 10.1007/s00277-018-3389-3
M3 - Article
C2 - 29872884
AN - SCOPUS:85048038474
SN - 0939-5555
VL - 97
SP - 1775
EP - 1783
JO - Annals of hematology
JF - Annals of hematology
IS - 10
ER -